Dr William Schilling
Will is a research physician working at the Mahidol Oxford Tropical Medicine Research Unit (MORU), a specialty registrar in Infectious diseases and Microbiology in the UK. He is a DPhil student at the University of Oxford.
Will has been working at MORU since August 2019 and had focussed on research into community febrile illness. Since January 2020 and the appearance of COVID-19, he has turned his attention to potential therapies which may prevent infection with COVID-19, including two widely available drugs, chloroquine and hydroxychloroquine, that demonstrated promising in vitro effects against SARS-CoV-2. At the time of writing, the COVID-19 pandemic is worsening and there are no prophylactic agents nor vaccines or proven-effective treatments available. The aim is to rapidly determine if these, and other drugs, can be used as prophylactic agents against COVID-19.
Will has previous experience working in Medicine in Mbarara, Uganda.
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK. et al, (2023), The Lancet. Infectious diseases
Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger.
Kabore Y. et al, (2023), The American journal of tropical medicine and hygiene, 109, 511 - 514
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)
Jittamala P. et al, (2023), The Journal of Infectious Diseases
Raising awareness of antimicrobial resistance: development of an ‘antibiotic footprint calculator’
Prapharsavat R. et al, (2023), Journal of Antimicrobial Chemotherapy, 78, 1317 - 1321
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial
Luvira V. et al, (2023)